Godot,
If we close above 8521 on the Dow, that would complete the Trannies recent high and put the market on a Dow theory buy signal.
BTW, I bought some cheap ICN May 10 calls today as a crapshoot for the earnings play, maybe ICN to consider for a candidate?
ICN Pharmaceuticals, Inc. to Announce First Quarter 2003 Results OnMonday, May 5
COSTA MESA, Calif., Apr 17, 2003 (BUSINESS WIRE) -- ICN Pharmaceuticals, Inc. (NYSE:ICN) announced today that it will host a conference call and webcast on Monday, May 5, 2003 at 10:00 a.m. EDT (7:00 a.m. PDT) to discuss results for the first quarter of 2003.
The dial-in number to participate live on this call is 877-356-3747, confirmation code 9753021. International callers should dial 706-643-7819, confirmation code 9753021. A replay will be available approximately two hours following the conclusion of the conference call through Monday, May 12, 2003, and can be accessed by dialing (800) 642-1687, confirmation code 9753021.
The company will also webcast the call live over the Internet, which will be hosted on the investor relations section of its corporate Web site at www.icnpharm.com. Participants should allow approximately five to ten minutes prior to the call's start time to visit the site and download any streaming media software needed to listen to the Internet webcast. An online archive of the webcast will be available following the end of the live call until Monday, June 2, 2003.
About ICN
ICN is an innovative, research-based global pharmaceutical company that manufactures, markets and distributes a broad range of prescription and non-prescription pharmaceuticals under the ICN brand name. Its research and new product development focuses on innovative treatments for dermatology, infectious diseases and cancer.
THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. This press release contains forward-looking statements that involve risks and uncertainties, including but not limited to, projections of future sales and royalty income, operating income, returns on invested assets, regulatory approval processes, success of the company's strategic repositioning initiatives and the ability of management to execute them, success of the company's ongoing inventory reduction program and other cost-cutting measures, the outcome of pending litigation, and other risks detailed from time to time in the company's Securities and Exchange Commission filings.
CONTACT: ICN Pharmaceuticals, Inc.
Investor Relations
Jeff Misakian, 714/545-0100, ext. 3230
jmisakian@icnpharm.com
or
Hill and Knowlton
Media Relations
Chris Kuechenmeister, 323/966-5709
chris.kuechenmeister@hillandknowlton.com
URL: businesswire.com
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.
Copyright (C) 2003 Business Wire. All rights reserved. |
